PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
Joint Authors
Gao, Xia
Feng, Xiaomeng
Jia, Yumei
Zhang, Heng
Pan, Qingrong
Yao, Zhi
Yang, Ning
Liu, Jia
Xu, Yuan
Wang, Guang
Yang, Xinchun
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-11-26
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Irisin is related to insulin resistance and metabolic disorders.
The physiologic effects of irisin are partially mediated through peroxisome proliferator-activated receptor-α (PPAR-α).
We investigated the effect of fenofibrate, a PPAR-α agonist, on serum irisin in type 2 diabetes patients with hypertriglyceridemia.
This study evaluated cross-sectional and interventional studies of 25 type 2 diabetes patients with hypertriglyceridemia (group A) and 40 controls (group B).
Group A was treated with fenofibrate (200 mg/day) for 8 weeks.
Serum irisin and clinical characteristics were examined.
Serum irisin was significantly higher in group A compared with group B (45.15±10.48 versus 35.38±9.97 ng/ml, P<0.001) and correlated with body mass index (r=0.314, P=0.011), fasting blood glucose (r=0.399, P=0.001), total cholesterol (r=0.256, P=0.040), and high-density lipoprotein cholesterol (r=0.247, P=0.047).
In multiple regression analysis after controlling for confounders, only fasting blood glucose (β=5.615, P<0.001) and high-density lipoprotein cholesterol (β=19.483, P<0.001) were independently related to serum irisin.
After 8 weeks of fenofibrate treatment, serum irisin significantly decreased in group A compared with baseline (45.15±10.48 versus 38.74±12.54 ng/ml, P=0.011).
Conclusively, fenofibrate decreased serum irisin in type 2 diabetes patients with hypertriglyceridemia, indicating that PPAR-α agonists may protect against metabolic disorders by improving irisin resistance.
American Psychological Association (APA)
Feng, Xiaomeng& Gao, Xia& Jia, Yumei& Zhang, Heng& Pan, Qingrong& Yao, Zhi…[et al.]. 2015. PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. PPAR Research،Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1075972
Modern Language Association (MLA)
Feng, Xiaomeng…[et al.]. PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. PPAR Research No. 2015 (2015), pp.1-8.
https://search.emarefa.net/detail/BIM-1075972
American Medical Association (AMA)
Feng, Xiaomeng& Gao, Xia& Jia, Yumei& Zhang, Heng& Pan, Qingrong& Yao, Zhi…[et al.]. PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. PPAR Research. 2015. Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1075972
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1075972